SiPhox upper-arm blood panel + BIOHM gut microbiome sequencing. Every metabolic, hormonal, inflammatory, and longevity marker that determines what your body actually needs.
Board-certified physicians review your full panel — not just outliers. They identify patterns, risks, and readiness. You receive a written clinical summary and a 30-minute interpretation call.
No generic protocol. Your biomarkers determine your stack. IGF-1 deficient — CJC-1295 + Ipamorelin. hs-CRP elevated — BPC-157. HOMA-IR above threshold — AOD-9604. Physician-prescribed via PCAB-accredited pharmacy.
Biology shifts. Your protocol shifts with it. Quarterly biomarker panels, body composition tracking, and physician protocol reviews keep your stack calibrated to where your biology is now — not where it was.
Sources: SCALE trial (Wilding et al, NEJM 2021) · GrimAge clock (Lu et al, Nature Aging 2019) · WellSpry patient cohort data. Peptide availability subject to formal FDA reclassification publication, expected August 2026.
The new WellSpry launches with limited early access slots. Join the waitlist for priority onboarding, founding member pricing, and a free blueprint before your testing kit arrives.
No spam. No commitment. Early access only — slots are limited.